Delphic Diagnostics

The story of modern diagnostics often involves identifying a very specific, challenging problem and applying a novel scientific approach. In 2016, a new chapter in this story began in Texas with the founding of Delphi Diagnostics, Inc. The company was established to commercialize the Endocrine Activity Index (EAI), a technology developed in the labs of The University of Texas MD Anderson Cancer Center. The goal was to provide more specific information to guide treatment for certain types of breast cancer. The company’s core technology, the EAI test, measures endocrine transcriptional activity in breast cancer patients. This allows doctors to better understand which patients might benefit most from particular chemotherapy regimens, moving beyond broad treatment categories toward more personalized medicine. A significant event in the company's journey was its acquisition. In late 2009, the business and assets of Delphic Diagnostics, a UK-based laboratory with expertise in virology and companion diagnostics, were acquired by Lab21. This move was part of Lab21's strategy to expand its molecular diagnostic services in the UK. It is important to note the distinction between the US-based Delphi Diagnostics Inc. focused on breast cancer and the UK-based Delphic Diagnostics involved in this acquisition. While sharing similar names, their founding origins and specific focus areas were different.